Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Mainz Biomed Inks Major Deal To Develop A Next-Generation Cancer Test By: News Direct November 22, 2024 at 09:30 AM EST --News Direct--By Johnny Rice, BenzingaMainz Biomed NV (NASDAQ: MYNZ) announced a major new collaborative agreement with Thermo Fisher Scientific Inc. (NYSE: TMO) to jointly develop a next-generation colorectal cancer screening product. The partnership will combine Thermo Fisher's advanced technologies with Mainz Biomed's proprietary mRNA-based screening tests, which focus on early detection of colorectal cancer and precancerous lesions.Mainz CEO Guido Baechler highlighted the collaboration's potential to accelerate the development of a home collection screening tool with effective cancer detection. The collaboration will utilize Mainz Biomed's laboratories in Mainz, Germany, to leverage both companies' capabilities in developing advanced cancer screening technologies.Learn more here:This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice.Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders.Contact DetailsBenzinga+1 877-440-9464info@benzinga.comCompany Websitehttp://www.benzinga.comView source version on newsdirect.com: https://newsdirect.com/news/mainz-biomed-inks-major-deal-to-develop-a-next-generation-cancer-test-351740583 Stock Quote API & Stock News API supplied by www.cloudquote.io Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
Mainz Biomed Inks Major Deal To Develop A Next-Generation Cancer Test By: News Direct November 22, 2024 at 09:30 AM EST --News Direct--By Johnny Rice, BenzingaMainz Biomed NV (NASDAQ: MYNZ) announced a major new collaborative agreement with Thermo Fisher Scientific Inc. (NYSE: TMO) to jointly develop a next-generation colorectal cancer screening product. The partnership will combine Thermo Fisher's advanced technologies with Mainz Biomed's proprietary mRNA-based screening tests, which focus on early detection of colorectal cancer and precancerous lesions.Mainz CEO Guido Baechler highlighted the collaboration's potential to accelerate the development of a home collection screening tool with effective cancer detection. The collaboration will utilize Mainz Biomed's laboratories in Mainz, Germany, to leverage both companies' capabilities in developing advanced cancer screening technologies.Learn more here:This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice.Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders.Contact DetailsBenzinga+1 877-440-9464info@benzinga.comCompany Websitehttp://www.benzinga.comView source version on newsdirect.com: https://newsdirect.com/news/mainz-biomed-inks-major-deal-to-develop-a-next-generation-cancer-test-351740583
--News Direct--By Johnny Rice, BenzingaMainz Biomed NV (NASDAQ: MYNZ) announced a major new collaborative agreement with Thermo Fisher Scientific Inc. (NYSE: TMO) to jointly develop a next-generation colorectal cancer screening product. The partnership will combine Thermo Fisher's advanced technologies with Mainz Biomed's proprietary mRNA-based screening tests, which focus on early detection of colorectal cancer and precancerous lesions.Mainz CEO Guido Baechler highlighted the collaboration's potential to accelerate the development of a home collection screening tool with effective cancer detection. The collaboration will utilize Mainz Biomed's laboratories in Mainz, Germany, to leverage both companies' capabilities in developing advanced cancer screening technologies.Learn more here:This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice.Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders.Contact DetailsBenzinga+1 877-440-9464info@benzinga.comCompany Websitehttp://www.benzinga.comView source version on newsdirect.com: https://newsdirect.com/news/mainz-biomed-inks-major-deal-to-develop-a-next-generation-cancer-test-351740583
